The Committee for the Japanese Respiratory Society guidelines in the management of respiratory infections. The Japanese Respiratory Society guidelines for the management of hospital-acquired pneumonia in adults. Respirology. 2004;9 Suppl 1:S1–S62.
The Committee for the Japanese Respiratory Society guidelines in the management of respiratory infections. The Japanese Respiratory Society guidelines for the management of community-acquired pneumonia in adults. Respirology. 2006;11 Suppl 3:S79–S133.
Ubukata K. Problems associated with high prevalence of multidrug-resistant bacteria in patients with community-acquired infections. J Infect Chemother. 2003;9:285–91.
Watanabe A, Yanagihara K, Kohno S, Matsushima T. HAP study group. Multicenter survey on hospital-acquired pneumonia and the clinical efficacy of first-line antibiotics in Japan. Intern Med. 2008;47:245–54.
Walsh TR, Toleman MA, Poirel L, Nordmann P. Metallo β-lactamases: the quiet before the storm? Clin Microbiol Rev. 2005;18:306–25.
Committee for Revision of MIC Determination Method. Revision of minimal inhibitory concentration (MIC) determination method (in Japanese). Chemotherapy (Tokyo). 1990;38:102–5.
Saito A, Inamatsu T, Okada J, Oguri T, Kanno H, Kusano N, et al. Clinical breakpoints in pulmonary infections and sepsis: new antimicrobial agents and supplemental information for some agents already released. J Infect Chemother. 1999;5:223–6.
Kadota J, Ishii Y, Kusachi S, Kusano N, Niki Y, Higa F, et al. Clinical breakpoints in pulmonary infections, sepsis and urinary tract infections: addition of new antimicrobial agents (2009). Jpn J Chemother. 2009;57:343–5. (in Japanese).
O’Callaghan CH, Morris A, Kirby SM, Shingler AH. Novel method for detection of β-lactamases by using a chromogenic cephalosporin substrate. Antimicrob Agents Chemother. 1972;1:283–8.
Arakawa Y, Shibata N, Shibayama K, Kurokawa H, Yagi T, Fujiwara H, et al. Convenient test for screening metallo-β-lactamase-producing gram-negative bacteria by using thiol compounds. J Clin Microbiol. 2000;38:40–3.
Hasegawa K, Yamamoto K, Chiba N, Kobayashi R, Nagai K, Jacobs MR, et al. Diversity of ampicillin-resistance genes in Haemophilus influenzae in Japan and the United States. Microb Drug Resist. 2003;9:39–46.
Ubukata K, Chiba N, Hasegawa K, Kobayashi R, Iwata S, Sunakawa K. Antibiotic susceptibility in relation to penicillin-binding protein genes and serotype distribution of Streptococcus pneumoniae strains responsible for meningitis in Japan, 1999 to 2002. Antimicrob Agents Chemother. 2004;48:1488–94.
Watanabe A, Fujimura S, Kikuchi T, Gomi K, Fuse K, Nukiwa T. Evaluation of dosing designs of carbapenems for severe respiratory infection using Monte Carlo simulation. J Infect Chemother. 2007;13:332–40.
Kuti JL, Ong C, Lo M, Melnick D, Soto N, Nicolau DP. Comparison of probability of target attainment calculated by Monte Carlo simulation with meropenem clinical and microbiological response for the treatment of complicated skin and skin structure infections. Int J Antimicrob Agents. 2006;28:62–8.
Saito A, Kohno S, Matsushima T, Watanabe A, Oizumi K, Yamaguchi K, et al. Prospective multicenter study of the causative organisms of community-acquired pneumonia in adults in Japan. J Infect Chemother. 2006;12:63–9.
Gomi K, Watanabe A, Aoki S, Kikuchi T, Fuse K, Nukiwa T, et al. Antibacterial activity of carbapenems against clinically isolated respiratory bacterial pathogens in Japan between 2005 and 2006. Int J Antimicrob Agents. 2007;29:586–92.
Hasegawa K, Chiba N, Kobayashi R, Murayama SY, Iwata S, Sunakawa K, et al. Rapidly increasing prevalence of β-lactamase-nonproducing, ampicillin-resistant Haemophilus influenzae type b in patients with meningitis. Antimicrob Agents Chemother. 2004;48:1509–14.
Kanazawa K, Nouda K, Sunagawa M. Structure-activity relationships of carbapenem compounds to anti-Haemophilus influenzae activity and affinity for penicillin-binding proteins: effect of 1-methyl group and C-2 side chain. J Antibiot. 1997;50:162–8.
Seki M, Watanabe A, Mikasa K, Kadota J, Kohno S. Revision of the severity rating and classification of hospital-acquired pneumonia in the Japanese Respiratory Society Guidelines. Respirology. 2008;13:880–5.
The Committee for the Japanese Respiratory Society guidelines in the management of respiratory infections. The Japanese Respiratory Society guidelines for the management of hospital-acquired pneumonia in adults. Respirology. 2009;14 Suppl 2:S1–S71.
Niki Y, Hanaki H, Matsumoto T, Yagisawa M, Kohno S, Aoki N, et al. Nationwide surveillance of bacterial respiratory pathogens conducted by the Japanese Society of Chemotherapy in 2007: general view of the pathogens’ antibacterial susceptibility. J Infect Chemother. 2009;15:156–67.
Sumita Y, Fukasawa M. Meropenem resistance in Pseudomonas aeruginosa. Chemotherapy. 1996;42:47–56.
Watanabe A, Kikuchi H, Kikuchi T, Lutfor AB, Tokue Y, Takahashi H, et al. Comparative in vitro activity of carbapenem antibiotics against respiratory pathogens isolated in recent years. J Infect Chemother. 1999;5:171–5.
Watanabe A, Tokue Y, Takahashi H, Kikuchi T, Kobayashi T, Gomi K, et al. Comparative in vitro activity of carbapenem antibiotics against respiratory pathogens isolated between 1999 and 2000. J Infect Chemother. 2001;7:267–71.